Literature DB >> 20582246

CAVITATION OF THE GHON FOCUS IN AN HIV-INFECTED INFANT WHO ACQUIRED TUBERCULOSIS AFTER THE INITIATION OF HAART.

S Innes1, H S Schaaf, M F Cotton.   

Abstract

Tuberculosis immune reconstitution inflammatory syndrome (IRIS) may present as new or worsening cavitation. We present an HIV-infected infant in whom TB infection and subsequent cavitation of the Ghon focus appeared to coincide with immune reconstitution due to highly active antiretroviral therapy (HAART). TB-IRIS in response to infection that occurs after starting HAART has not previously been described.

Entities:  

Year:  2009        PMID: 20582246      PMCID: PMC2892256     

Source DB:  PubMed          Journal:  South Afr J HIV Med        ISSN: 1608-9693            Impact factor:   2.744


  6 in total

1.  Pediatric HIV immune reconstitution inflammatory syndrome.

Authors:  David R Boulware; Steven Callens; Savita Pahwa
Journal:  Curr Opin HIV AIDS       Date:  2008-07       Impact factor: 4.283

2.  The time-table of tuberculosis.

Authors:  A WALLGREN
Journal:  Tubercle       Date:  1948-11

3.  Age-related standards for total lymphocyte, CD4+ and CD8+ T cell counts in children born in Europe.

Authors:  Madeleine Bunders; Mario Cortina-Borja; Marie-Louise Newell
Journal:  Pediatr Infect Dis J       Date:  2005-07       Impact factor: 2.129

4.  Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART.

Authors:  Beate Kampmann; Gwen N Tena-Coki; Mark P Nicol; Michael Levin; Brian Eley
Journal:  AIDS       Date:  2006-04-24       Impact factor: 4.177

5.  Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy.

Authors:  Neil W Schluger; Daniel Perez; Yuk Ming Liu
Journal:  Chest       Date:  2002-08       Impact factor: 9.410

6.  T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection.

Authors:  Timo Ulrichs; D Branch Moody; Ethan Grant; Stefan H E Kaufmann; Steven A Porcelli
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.